2 results match your criteria: "Stanford Center of Excellence for Sleep Disorders[Affiliation]"
Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome.
Clin Neuropharmacol
May 2009
Stanford Center of Excellence for Sleep Disorders, 401 Quarry Road, Suite 3301-A, Stanford, CA 94305-5730, USA.
Objectives: To investigate the effect of twice-daily ropinirole in patients with early evening restless legs syndrome (RLS) symptoms, particularly focusing on the relationship of patient- and physician-rated assessment of treatment outcomes.
Methods: In this multicenter, double-blind, randomized, 12-week, flexible-dose study, patients with primary RLS, with symptom onset no earlier than 5 PM and a baseline International Restless Legs Syndrome Study Group Rating Scale (IRLS) total score > or = 20 received ropinirole 0.5 to 6.
Burden of restless legs syndrome on health-related quality of life.
Qual Life Res
May 2007
Stanford Center of Excellence for Sleep Disorders, Stanford, CA, USA.
Objective: To quantify the total and unique burden of Restless Legs Syndrome (RLS) on patient-reported health-related quality of life (HRQoL).
Methods: The disease burden that RLS places on HRQoL was estimated by comparing Short-Form (SF-36) scores between individuals with RLS and several patient and general populations in the US. Regression methods were applied to estimate SF-36 normative values from the general population sample and statistically adjust them to match age, gender and disease comorbidity characteristics of the RLS sample.